LOS ANGELES, Oct. 29, 2018 /PRNewswire/ -- CytRx Corporation
(NASDAQ: CYTR), a biopharmaceutical research and development
company specializing in oncology, today announced that it will
report financial results for the quarter ended September 30, 2018 on Friday, November 2, 2018. CytRx executives
Eric L. Curtis, President and Chief
Operating Officer, and John Caloz,
Chief Financial Officer, will hold a conference call and webcast
beginning at 11:00 a.m. Eastern Time
(8:00 a.m. Pacific Time) on that day
to discuss the financial results as well as provide an overview of
corporate strategy and achievements.
To access the conference call, dial (+1)844-358-6753 (U.S.
and Canada) or (+1)216-562-0397 (international callers) and
enter the conference ID number: 4382473. A live and archived
webcast will be available in the investor relations section of the
company's website, www.cytrx.com. A replay of the call and
webcast will begin approximately two hours after the live call has
ended. To access the replay, dial (+1)855-859-2056 (U.S.
and Canada) or (+1)404-537-3406 (international callers) and
enter the conference ID number: 4382473.
About CytRx Corporation
CytRx Corporation (NASDAQ: CYTR) is a biopharmaceutical company
with expertise in discovering and developing new therapeutics to
treat patients with cancer. CytRx's most advanced drug conjugate,
aldoxorubicin, is an improved version of the widely used
anti-cancer drug doxorubicin and has been out-licensed to NantCell,
Inc. In addition, CytRx's other drug candidate, Alrimoclomol has
been out-licensed to Orphazyme A/S (Nasdaq Copenhagen exchange).
Orphazyme is testing Arimoclomol in four indications including
amyotrophic lateral sclerosis (ALS), Niemann-Pick disease Type C
(NPC), Gaucher disease and sporadic Inclusion Body Myositis
(sIBM).
About Centurion BioPharma Corporation
CytRx's wholly owned subsidiary, Centurion BioPharma
Corporation, is focused on the development of personalized medicine
that will transform solid tumor treatment. This transformational
strategy combines a portfolio of novel, anti-cancer drug candidates
that employ LADR™ (Linker Activated Drug Release) technology, a
discovery engine designed to leverage Centurion's expertise in
albumin biology and linker technology for the development of a new
class of breakthrough anti-cancer therapies with a unique albumin
companion diagnostic (ACDx) that can help identify patients who are
most likely to benefit from treatment with the LADR™-derived
therapies. A critical element of the LADR™ platform is its ability
to bind anti-cancer molecules to circulating albumin, the most
ubiquitous protein in human blood plasma, and then to release the
highly potent cytotoxic payload at the tumor site. This technology
allows for the delivery of higher doses of drug directly to the
tumor, while avoiding much of the off-target toxicity observed with
the parent molecules.
Forward-Looking Statements
This press release contains forward-looking statements. Such
statements involve risks and uncertainties that could cause actual
events or results to differ materially from the events or results
described in the forward-looking statements, including risks and
uncertainties relating to the ability of NantCell, Inc., to obtain
regulatory approval for its products that use aldoxorubicin; the
ability of NantCell, Inc., to manufacture and commercialize
products or therapies that use aldoxorubicin; the amount, if any,
of future milestone and royalty payments that we may receive from
NantCell, Inc.; Centurion BioPharma Corporation's ability to
develop new ultra-high potency drug candidates based on its LADR™
technology platform; our ability to attract potential licensees;
and other risks and uncertainties described in the most recent
annual and quarterly reports filed by CytRx with the Securities and
Exchange Commission and current reports filed since the date of
CytRx's most recent annual report. All forward-looking statements
are based upon information available to CytRx on the date the
statements are first published. CytRx undertakes no obligation to
publicly update or revise any forward-looking statements, whether
as a result of new information, future events or otherwise.
Investor Relations Contact:
Argot Partners
Michelle Carroll
(212) 600-1902
michelle@argotpartners.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/cytrx-to-hold-third-quarter-2018-financial-results-conference-call-and-webcast-on-friday-november-2-2018-300738939.html
SOURCE CytRx Corporation